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Fluoroscopy with MRA fusion image
guidance in endovascular iliac artery
interventions: study protocol for a
randomized controlled trial (3DMR-Iliac-
roadmapping study)
Seline R. Goudeketting1* , Stefan G. H. Heinen1, Michiel W. de Haan2, Anna M. Sailer3,
Daniel A. F. van den Heuvel4, Marco J. van Strijen4 and Jean-Paul P. M. de Vries5
Abstract
Background: Endovascular iliac artery interventions rely on the use of two-dimensional digital subtraction
angiographies with an iodinated contrast agent and ionizing radiation. The amount of iodinated contrast agent
should be limited because of its potentially nephrotoxic effects. Three-dimensional (3D) image fusion requires
registration of a preprocedural magnetic resonance angiogram (MRA) or computed tomography (CT) angiogram to
a perprocedurally acquired cone-beam CT or two fluoroscopic orthogonal projections. After registration, the 3D
angiography images can be overlaid on the fluoroscopy screen and will follow table and C-arm movements. This
study will assess the added value of the 3D image fusion technique in iliac artery interventions regarding the
amount of the iodinated contrast agent administered.
Methods/Design: The study cohort will comprise 106 patients (> 18 years) with symptomatic common and/or
external iliac artery stenoses or occlusions and a recent (< 6 months) diagnostic MRA from the pelvis through the
lower extremities, for which an endovascular intervention is indicated. Patients will be randomized into the control
or study group (i.e. treatment without or with 3D image fusion guidance). The primary endpoint is the amount of
administered iodinated contrast agent (mL). Secondary outcomes are technical success of the procedure, defined as
< 30% residual stenosis over the treated lesion, fluoroscopy time, and radiation dose as dose area product
(mGycm2). Patient participation in the study will be completed after hospital discharge.
Discussion: This study is a randomized controlled multicenter trial to provide evidence on the effect of the 3D
image fusion technique on the amount of administered iodinated contrast during endovascular common and/or
external iliac artery interventions.
Trial registration: Nederlands Trial Register, NTR5008. Registered on 16 December 2014.
Keywords: 3D imaging, Fusion imaging, Cone-beam computed tomography, Magnetic resonance angiography,
Iliac artery, Angioplasty
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Background
The iliac arteries are involved in up to 30% of patients with
peripheral artery disease (PAD) [1]. The preferred treatment
for most patients is endovascular revascularization (i.e. per-
cutaneous transluminal angioplasty [PTA] or recanalization)
with optional stent placement. Two-dimensional (2D) digital
subtraction angiography (DSA) with iodinated contrast agent
and ionizing radiation is the gold standard to visualize the lo-
cation and severity of the lesion [1]. Because of its potentially
nephrotoxic effects, especially in patients with pre-existing
renal failure or diabetes mellitus, the amount of iodinated
contrast agent should be limited [2, 3].
Non-invasive imaging acquired before the procedure,
such as contrast-enhanced magnetic resonance angiog-
raphy (MRA) or computed tomography angiography
(CTA), can be used as guidance during these endovascu-
lar interventions. The three-dimensional (3D) image fu-
sion technique is based on the rigid registration of MRA
or CTA to a perprocedurally acquired cone-beam com-
puted tomography (CBCT) or, alternatively, two fluoro-
scopic orthogonal images. This registration is based on
bony landmarks, after which the MRA images will be vi-
sualized on the 2D fluoroscopy screen (Fig. 1). Because
of the registration, the MRA images will follow table and
C-arm movements. The 3D image fusion technique does
not require the use of additional iodinated contrast
agent and has shown to significantly reduce the amount
of iodinated contrast agent during endovascular abdom-
inal aortic aneurysm repair (EVAR) [4–8].
No randomized controlled trials have been performed
to assess the added value of the 3D image fusion tech-
nique in iliac artery interventions so far.
Hypothesis
The hypothesis of this trial is that the use of the 3D
image fusion technique will result in a significant reduc-
tion of the amount of administered iodinated contrast
agent during endovascular iliac artery interventions
compared with the endovascular iliac artery procedures
without the use of the 3D image fusion technique.
Methods/Design
Study design
This is a prospective randomized, controlled, multicen-
ter trial. The flow diagram of the trial is shown in Fig. 2.
The SPIRIT figure can be found in Fig. 3 and the check-
list is available in Additional file 1.
Study objectives and endpoints
The primary endpoint is the amount of administered io-
dinated contrast agent (mL). The intra-arterial iodinated
contrast agents Ultravist (300 mg/mL; Bayer Vital, Le-
verkusen, Germany) and Xenetix (300 mg/mL; Guerbet,
Roissy, France) will be used during all interventions of
the Maastricht University Medical Center (MUMC) and
St. Antonius Hospital (SAH), respectively.
Secondary endpoints are the following:
1. Technical success of the procedure, defined as <
30% trans-lesion residual stenosis and no flow-
limiting dissections;
2. Fluoroscopy time from the start to end of the
procedure in minutes and seconds;
3. Overall procedure time, defined as the time from
femoral access to arterial closure (minutes);
4. Radiation dose as dose area product (DAP) in
mGycm2 from the start to the end of the
procedure;
5. Fusion accuracy between the overlaid MRA and
DSA, categorized as accurate (< 2 mm), mismatch
(2–5 mm), or inaccurate (> 5 mm);
6. Complications that occur during the intervention
and before discharge.
Fig. 1 Example of fluoroscopy with MRA fusion image guidance. a, b Coronal and sagittal view of the image registration process (the cone-beam
CT images in red and the MRA images in blue). c An example of the fusion image guidance during a digital subtraction angiography
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Patients
The study cohort will comprise 106 patients (> 18 years)
with symptomatic common iliac artery (CIA) and/or ex-
ternal iliac artery (EIA) stenoses or occlusions and Ruth-
erford category 1–6, a recent (< 6 months) diagnostic
MRA from the pelvis through the lower extremities, and
an indication of endovascular intervention (PTA or re-
canalization). Participants will be randomized 1:1 to the
control or study group (i.e. standard PTA or recanaliza-
tion with or without the 3D image fusion technique). Pa-
tients will be included from the MUMC and SAH.
Inclusion and exclusion criteria are summarized in
Table 1.
Randomization
Randomization will be performed by the investigators
with the use of an automated web-based randomization
and electronic data capture software (MACRO 4.6.0,
https://ecrf.ctcm.nl/macro). Randomization will be per-
formed according to minimization; for a difference of 2
between the two groups (control and study group), there
is a 90% chance that the next individual will be allocated
to the group with the smallest number of patients.
Stratification factors are the site (MUMC or SAH),
weight (≤ 90 or > 90 kg), and estimated glomerular filtra-
tion rate (eGFR) (≤ 60 or > 60 mL/min/1.73m2). It is ex-
pected that the site, weight and eGFR have the biggest
impact on the outcome measures. First, the groups
should be similar regarding renal function because this
may affect outcome. It can be argued that in patients
with a reduced renal function, physicians are more care-
ful with the amount of administered contrast. Thus, by
using the eGFR as a stratification factor, this bias will be
minimized. Second, the radiation dose is taken into ac-
count, which is dependent on the patients’ weight.
Therefore, stratification on weight is important. Third, it
is not preferable to have one of the sites primarily per-
forming the interventions with the 3D fusion technique
and vice versa, since that would influence the user ex-
perience and is possibly also be related to the amount of
contrast volume that is administered and the radiation
dose that is used. Hence, these stratification factors were
chosen to keep the distribution between the groups
equal. Owing to the nature of the study, randomization
will not be blinded for patients or physicians.
Ethics
The study will be conducted in accordance with the
principles of the Declaration of Helsinki and the Medical
Research Involving Human Subjects Act (in Dutch: Wet
Medisch Wetenschappelijk Onderzoek met Mensen).
The local medical ethical committees of both hospitals
have approved the study protocol (NL47680.068.14, ver-
sion 1.4). The study protocol was registered at the
Netherlands Trial Register at www.trialregister.nl on 16
December 2014 (registration number: NTR5008). All pa-
tients will give written informed consent before study in-
clusion and randomization. Patient participation is
voluntary; the participant can request to stop participa-
tion to the study at any time.
Sample size calculation and statistical analysis
The sample size was calculated using a two-tailed t-test
with null hypothesis E(D) = 0 (no difference between the
groups) and alternative hypothesis E(D) ≠ 0 (groups are
Fig. 2 Flow diagram of the trial
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different). A type I error (α) of 0.05 with z-value Zα ≈







with N the sample size and σD the expected standard de-
viation. When assuming the alternative hypothesis is
true E(D) = τ the power (π(τ)) can be calculated by







with Φ being the Phi coefficient. When accepting a
power of at least 0.90, the alternative hypothesis for E(D)
= τ can be estimated by
Table 1 Eligibility criteria
Inclusion Exclusion
Patients with PAD of the CIA and/or EIA
for which an endovascular intervention is
indicated
Age < 18 years
Rutherford class 1–6 Treatment for acute arterial
ischemia
A recent (< 6 months) diagnostic MRA
from the pelvis through the lower
extremities with sufficient quality without
artifacts (e.g. in stent restenosis or patient
movement)
Allergy for iodinated contrast
agents
Signed informed consent Patients with aneurismal
lesions of the iliac artery
Pregnancy or breast-feeding
STUDY PERIOD
Enrolment Day of the intervention































Fig. 3 Schedule of enrolment, interventions, and assessments*
Goudeketting et al. Trials          (2018) 19:603 Page 4 of 8





















> 1:96þ Zβ ¼ 1:96þ 1:28 ≈ 3:24 ð5Þ
Given that half of the proportion of the study patients
is randomized into the control group (q0 = 0.5) and the
other half in the study group (q1 = 1 − q0 = 0.5), the sam-












Based on earlier research [9], we expect that τ =
20 mL of administered contrast volume may be reduced
with the use of the 3D image fusion technique by redu-
cing the number of contrast runs by at least two.
Full-strength iodinated contrast is diluted 50:50 with a
normal saline solution because a lower concentration of
iodinated contrast agent has been shown not to com-
promise image quality during DSA of PAD patients [10].
To achieve a reduction of 20 mL per procedure with a
mean volume of 60 mL and corresponding standard de-
viation of σD = 30 mL, the sample size N becomes a total
of 96 patients. Therefore, 48 patients will be needed in
each group. Adjusting for an anticipated loss to
follow-up of 10%, the total sample size will be 106 pa-
tients. An interim analysis will be performed halfway
through, after inclusion of the first 40 patients, to assess
the efficacy of the 3D fusion technique compared to the
control group.
Normal distribution of the data will be tested. Nor-
mally distributed data will be represented as the mean
and 95% confidence interval; non-normally distributed
data will be represented as the median and interquartile
range. Continuous variables will be analyzed with the in-
dependent samples t-test or Mann–Whitney U test for
normally and non-normally distributed data, respect-
ively. Categorical data will be analyzed with the χ2 test.
All tests will be two-sided and considered significant
when P < 0.05.
Intervention
The aim of the endovascular treatment is to obtain a pa-
tent CIA and/or EIA (i.e. < 30% residual stenosis or a re-
duction of the mean pressure gradient to < 10 mmHg
[11]), resulting in an improved blood flow to the legs. In
case of a flow limiting dissection, > 30% residual sten-
osis, or acute elastic recoil after PTA, additional stent
placement will be performed. If indicated, other arteries
will be treated in addition to the CIA and/or EIA during
the same intervention. The physician will choose an ipsi-
lateral or contralateral technique (or rendezvous proced-
ure), depending on the location of the lesion. The
analysis will not include data of patients with solely diag-
nostic DSAs.
Before the start of the intervention, the patient will be
placed supine on the angiography table. The contrast
pump and table contrast agent will be diluted 50:50 with
a normal saline solution. For patients randomized into
the study group, a non-contrast-enhanced CBCT will be
created at the beginning of the intervention using the
flat panel detector of the C-arm angiography system
(Allura Xper FD20; Philips Healthcare). The CBCT will
be automatically transferred to the 3D XtraVision work-
station (Philips Healthcare). Subsequently, a manual
3D-3D registration will be performed between the pre-
procedural MRA and CBCT based on bony landmarks,
such as vertebrae and the femoral heads, and the flow
lumen on the MRA will be matched to the border of the
calcifications as seen on the CBCT. The time required
to perform the registration will be recorded.
After the registration, the physician will visually score
the fusion accuracy of the entire iliac vasculature be-
tween the overlay and the initial DSA run. This fusion
accuracy will be determined directly after the DSA is
created and will be categorized as accurate (< 2 mm),
mismatch (2–5 mm), or inaccurate (> 5 mm). An overlay
that is inaccurate will be manually translated or reregis-
tered to achieve a more accurate overlay that will be
used during the intervention. Subsequently, the inter-
vention will be performed according to the standard of
care procedure and contrast runs will be performed
when needed.
DSAs will be performed with 15 mL at 12 mL/s or
8 mL at 4 mL/s using a catheter in the aorta or CIA, re-
spectively. A completion DSA will be created to confirm
procedural success. DSA runs, whether or not in com-
bination with the overlay (for the study group), will be
stored. Primary and secondary endpoints will be regis-
tered, as well as baseline characteristics and procedural
details, including ipsilateral or contralateral, length and
location of the lesion, type of PTA balloon or stent, and
number of stents.
All patients will receive 5000 IU of heparin during the
intervention. The patients will receive bed rest after the
intervention according to the physician’s prescription. All
patients will be prescribed acetylsalicylic acid (ASA or as-
pirin) at 80 mg/d. The PTA and recanalization procedures
are generally performed as outpatient procedures. Patient
participation in the study will be completed after discharge.
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Any complication that occurs between the signed informed
consent and hospital discharge will be recorded. There is
no further follow-up period for this study.
Data collection
Data will be collected by use of an electronic case report
form (eCRF), which will be prospectively maintained
from the time the patient signs the informed consent
until the completion of the study. Patient data will be
anonymized; each individual will be given a unique study
number (site code [MUMC/ANTO] and index number).
Each center can only view and add eCRF data from its
own site. At the end of the study, the eCRFs of both
sites will be become available to both centers.
Monitoring and adverse events
A Data and Safety Monitoring Board (DSMB) will not
be appointed for this study. A qualified monitor of the
Clinical Trial Center Maastricht (CTCM) will monitor
the study, which will ensure that the study is conducted
according to ICH-GCP guidelines. Visits are conducted
at the start of the study, after inclusion of five patients,
halfway through, and at completion of the study. A
monitoring report will be sent to the investigator after
each visit.
Adverse events and serious adverse events will be re-
corded on the eCRFs. They will comprise a description
of the event, type of complication (i.e. access site, sys-
temic, organ-specific), severity, start date, end date,
whether suspected to be intervention related, any action
that is undertaken, and the outcome. Serious adverse
events will be reported to the accredited METC through
the “Toetsingsonline” page of the website of the Central
Committee on Research Involving Human Subjects (in
Dutch: Centrale Commissie Mensgebonden Onderzoek,
CCMO [www.ccmo.nl]). The investigator will report ser-
ious adverse device events resulting from the use of the
3D image fusion technique to the accredited METC, the
manufacturer, and the Inspection for Healthcare (in
Dutch: Inspectie voor Gezondheidszorg [IGZ]).
Discussion
The use of angiography during endovascular interventions
is essential to visualize stenotic or obstructive lesions [12].
With increasing complexity of procedures, the amount of
iodinated contrast agent may increase. The potentially
nephrotoxic effects of the iodinated contrast agent are es-
pecially problematic in patients with pre-existing renal
failure [2, 13, 14]. A recent systematic review confirmed
that the amount of administered iodinated contrast agent
can be significantly reduced by using the 3D image tech-
nique during EVAR procedures [15]. In addition, the radi-
ation dose, procedure time, and fluoroscopy time may be
reduced during these procedures [15], which could be
beneficial to physicians, who receive high exposure to ra-
diation throughout their practice.
A vacuum mattress can be used to reduce patient
movement [16], which can minimize overlay inaccuracy
caused by movement artifacts. We assume that move-
ment artifacts will be smaller in the pelvic area than in
the legs and that registration in this area will be less
challenging because of the bony structures (vertebrae,
femoral head, and iliac crest) and larger diameters of the
arteries. This research focuses on the iliac arteries; when
this study demonstrates the benefits of the 3D fusion
technique in endovascular iliac artery interventions, the
technique can be extended to femoro-crural lesions.
An alternative to iodinated contrast agents is the use of
angiography based on carbon dioxide (CO2). The use of
CO2 during EVAR procedures is safe and reliable and may
be especially beneficial for patients with renal insufficiency
[17]. However, variability in image quality has been re-
ported and a careful technique is required for each injection
to prevent air contamination. Additionally, there is a possi-
bility of pain after injection, and CO2 for intravascular use
has the potential for air embolism, which could result in is-
chemia or tissue infarction [18]. Although CO2 may be able
to replace nephrotoxic contrast agents and reduce iodine
contrast agent costs [18, 19], it will probably not reduce the
radiation doses to patient and staff. Carbon dioxide and the
3D image fusion technique can be complementary during
(complex) EVAR [20, 21]; however, 3D fusion in combin-
ation with CO2 for iliac artery interventions has not yet
been investigated.
Preoperative MRA or CTA can be used for 3D image
guidance. Registration between two similar image mo-
dalities (i.e. CTA to CBCT) may be less challenging than
registration between MRA and CBCT, because MRA vi-
sualizes the flow lumen of the arteries, instead of calci-
fied speculae. Nevertheless, because an MRA of the
lower abdomen, pelvis, and lower extremities is the
standard diagnostic imaging in the preoperative work-
flow of many patients with PAD, only patients with pre-
operative MRA datasets will be included; therefore,
patients with contraindications to MRA are not eligible.
Furthermore, because of susceptibility artifacts on the
MRA, in-stent stenoses cannot be judged and those pa-
tients will not be included in this trial. No additional
preoperative imaging needs to be performed for this
study and patient burden is minimized.
Image registration can be performed to a CBCT (3D-3D
image fusion) or two fluoroscopic orthogonal projections
(2D-3D image fusion). The acquisition of a CBCT and
registration process takes approximately 5–10 min and is
reported to be more accurate than 2D-3D image fusion
[20]. However, the latter is reported to be fast and can be
performed with a minimal effective dose of 0.14–0.20 mSv
[21]. Sailer et al. [22] reported that a CBCT corresponds
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to a mean effective dose of 3.5 mSv (95% confidence inter-
val, 3.0–4.1 mSv), whereas van den Berg [21] reported an
effective dose of 1.53–1.66 mSv. The patient’s radiation
dose from a CBCT may add 21% of the total procedural
DAP for iliac artery interventions [9], which is comparable
to approximately 7 min of fluoroscopy time [22]. During
fluoroscopy, the physician is at the tableside, but is usually
far away from the C-arm during the acquisition of the
CBCT. When the 3D fusion technique is used during
EVAR, the fluoroscopy time could be significantly reduced
[23, 24]. This reduction may also be feasible for iliac artery
interventions, which will be beneficial to both the operator
and the patient, and could potentially result in a reduction
of costs. The possible benefit for contrast saving, com-
bined with the possible reduction of fluoroscopy time
might outweigh the additional radiation dose of a CBCT.
Trial status
The METC has approved the study protocol. Currently, 40
patients have been enrolled in the 3DMR-Iliac-Roadmapping
study. The expected project completion for this trial is De-
cember 2018.
Additional file
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents*. (DOC 121 kb)
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